Chappell, L. C., Cluver, C. A., Kingdom, J. & Tong, S. Pre-eclampsia. Lancet 398, 341â354 (2021).
Swingle, K. L., Ricciardi, A. S., Peranteau, W. H. & Mitchell, M. J. Delivery technologies for womenâs health applications. Nat. Rev. Bioeng. 1, 408â425 (2023).
Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New Engl. J. Med. 379, 11â21 (2018).
Geisler, H. C., Safford, H. C. & Mitchell, M. J. Rational design of nanomedicine for placental disorders: birthing a new era in womenâs reproductive health. Small 20, 2300852 (2023).
Gilbert, J. S. et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 55, 380â385 (2010).
Mateus, J. et al. Endothelial growth factor therapy improves preeclampsia-like manifestations in a murine model induced by overexpression of sVEGFR-1. Am. J. Physiol. Heart Circ. Physiol. 301, H1781âH1787 (2011).
Li, Z. et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686â692 (2007).
David, A. L. et al. Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther. 15, 1344â1350 (2008).
David, A. L. Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction. Placenta 59, S44âS50 (2017).
Mehta, V. et al. Long-term increase in uterine blood flow is achieved by local overexpression of VEGF-A 165 in the uterine arteries of pregnant sheep. Gene Ther. 19, 925â935 (2012).
Carr, D. J. et al. Uteroplacental adenovirus vascular endothelial growth factor gene therapy increases fetal growth velocity in growth-restricted sheep pregnancies. Hum. Gene Ther. 25, 375â384 (2014).
Woods, A. K. et al. Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 57, 94â102 (2011).
Haase, N. et al. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models. J. Clin. Invest. 130, 2928â2942 (2020).
Turanov, A. A. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 36, 1164â1173 (2018).
Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541â555 (2014).
Swingle, K. L., Hamilton, A. G. & Mitchell, M. J. Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines. Trends Mol. Med. 27, 616â617 (2021).
Polack Fernando, P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl. J. Med. 383, 2603â2615 (2020).
Baden Lindsey, R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl. J. Med. 384, 403â416 (2021).
Sato, Y., Kinami, Y., Hashiba, K. & Harashima, H. Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway. J. Control. Release 322, 217â226 (2020).
Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPRâCas gene editing. Nat. Nanotechnol. 15, 313â320 (2020).
Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).
LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, K. A. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J. Control. Release 345, 819â831 (2022).
Swingle, K. L. et al. Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy. J. Am. Chem. Soc. https://doi.org/10.1021/jacs.2c12893 (2023).
Young, R. E. et al. Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach. Bioact. Mater. 34, 125â137 (2024).
Chaudhary, N. et al. Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes. Proc. Natl Acad. Sci. USA 121, e2307810121 (2024).
Safford, H. C. et al. Orthogonal design of experiments for engineering of lipid nanoparticles for mRNA delivery to the placenta. Small 20, e2303568 (2024).
Geisler, H. C. et al. EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta. J. Control. Release 371, 455â469 (2024).
Paunovska, K. et al. A direct comparison of in vitro and in vivo nucleic acid selivery mediated by hundreds of nanoparticles reveals a weak correlation. Nano Lett. 18, 2148â2157 (2018).
Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060â2065 (2017).
Huayamares, S. G. et al. High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo. J. Control. Release 357, 394â403 (2023).
El-Mayta, R. et al. A nanoparticle platform for accelerated in vivo oral delivery screening of nucleic acids. Adv. Ther. 4, 2000111 (2021).
Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864â1869 (2010).
Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172â176 (2010).
Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. 124, 8657â8661 (2012).
Dusse, L. M. et al. Revisiting HELLP syndrome. Clin. Chim. Acta 451, 117â120 (2015).
Fenton, O. S. et al. Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 29, 1606944 (2017).
Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926â9937 (2022).
Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive Sscreening designs. Nano Lett. 15, 7300â7306 (2015).
Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533â542 (2022).
Swingle, K. L. et al. Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery. J. Control. Release 341, 616â633 (2022).
Veiga, N. et al. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat. Commun. 9, 4493 (2018).
Parhiz, H. et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J. Control. Release 291, 106â115 (2018).
Shi, D., Toyonaga, S. & Anderson, D. G. In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Lett. 23, 2938â2944 (2023).
Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436â443 (2023).
Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467â1475 (2017).
Irvin-Choy, N. S., Nelson, K. M., Dang, M. N., Gleghorn, J. P. & Day, E. S. Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age. Nanomed. Nanotechnol. Biol. Med. 36, 102412 (2021).
Raz, T. et al. The hemodynamic basis for positional- and inter-fetal dependent effects in dual arterial supply of mouse pregnancies. PLoS ONE 7, e52273 (2012).
Kertschanska, S., Kosanke, G. & Kaufmann, P. Pressure dependence of so-called transtrophoblastic channels during fetal perfusion of human placental villi. Microsc. Res. Tech. 38, 52â62 (1997).
Kertschanska, S., Stulcová, B., Kaufmann, P. & Stulc, J. Distensible transtrophoblastic channels in the rat placenta. Placenta 21, 670â677 (2000).
Francia, V., Schiffelers, R. M., Cullis, P. R. & Witzigmann, D. The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjug. Chem. 31, 2046â2059 (2020).
Bashiri, G. et al. Nanoparticle protein corona: from structure and function to therapeutic targeting. Lab Chip 23, 1432â1466 (2023).
Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357â1364 (2010).
Chamley, L. W., Allen, J. L. & Johnson, P. M. Synthesis of β2 glycoprotein 1 by the human placenta. Placenta 18, 403â410 (1997).
Robertson, S. A. et al. Effect of β2âglycoprotein I null mutation on reproductive outcome and antiphospholipid antibodyâmediated pregnancy pathology in mice. Mol. Hum. Reprod. 10, 409â416 (2004).
Waker, C. A., Kaufman, M. R. & Brown, T. L. Current state of preeclampsia mouse models: approaches, relevance, and standardization. Front. Physiol. 12, 681632 (2021).
Ding, X., Yang, Z., Han, Y. & Yu, H. Correlation of long-chain fatty acid oxidation with oxidative stress and inflammation in pre-eclampsia-like mouse models. Placenta 36, 1442â1449 (2015).
Huai, J., Yang, Z., Yi, Y.-H. & Wang, G.-J. Different effects of pravastatin on preeclampsia-like symptoms in different mouse models. Chin. Med. J. (Engl.) 131, 461â470 (2018).
Swingle, K. L., Hamilton, A. G. & Mitchell, M. J. Flow cytometric analysis of the murine placenta to evaluate nanoparticle platforms during pregnancy. Placenta https://doi.org/10.1016/j.placenta.2024.08.007 (2024).
Umapathy, A., Chamley, L. W. & James, J. L. Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis 23, 105â117 (2020).
Aneman, I. et al. Mechanisms of key innate immune cells in early- and late-onset preeclampsia. Front. Immunol. 11, 1864 (2020).
Bergmann, A. et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14, 1857â1867 (2010).
Wu, H. et al. Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci. Transl. Med. 8, 331ra40 (2016).
Hamilton, A. G., Swingle, K. L. & Mitchell, M. J. Biotechnology: overcoming biological barriers to nucleic acid delivery using lipid nanoparticles. PLoS Biol. 21, e3002105 (2023).
Yan, Y. et al. Non-viral vectors for RNA delivery. J. Control. Release 342, 241â279 (2022).
Stefanovic, V. International Academy of Perinatal Medicine (IAPM) guidelines for screening, prediction, prevention and management of pre-eclampsia to reduce maternal mortality in developing countries. J. Perinat. Med. 51, 164â169 (2023).
Pardi, N., Muramatsu, H., Weissman, D. & Karikó, K. in Synthetic Messenger RNA and Cell Metabolism Modulation: Methods and Protocols Vol. 969 (ed. Rabinovich, P. M.) 29â42 (Humana, 2013).
Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833â1840 (2008).
Weissman, D., Pardi, N., Muramatsu, H. & Karikó, K. in Synthetic Messenger RNA and Cell Metabolism Modulation: Methods and Protocols (ed. Rabinovich, P. M.) 43â54 (Humana, 2013).
Zhang, R. et al. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. Biomater. Sci. 9, 1449â1463 (2021).
Chen, D. et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Am. Chem. Soc. 134, 6948â6951 (2012).
Hajj, K. A. et al. Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal pH. Small 15, 1805097 (2019).
